chlorambucil has been researched along with Polycythemia Vera in 49 studies
Chlorambucil: A nitrogen mustard alkylating agent used as antineoplastic for chronic lymphocytic leukemia, Hodgkin's disease, and others. Although it is less toxic than most other nitrogen mustards, it has been listed as a known carcinogen in the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (Merck Index, 11th ed)
chlorambucil : A monocarboxylic acid that is butanoic acid substituted at position 4 by a 4-[bis(2-chloroethyl)amino]phenyl group. A chemotherapy drug that can be used in combination with the antibody obinutuzumab for the treatment of chronic lymphocytic leukemia.
Polycythemia Vera: A myeloproliferative disorder of unknown etiology, characterized by abnormal proliferation of all hematopoietic bone marrow elements and an absolute increase in red cell mass and total blood volume, associated frequently with splenomegaly, leukocytosis, and thrombocythemia. Hematopoiesis is also reactive in extramedullary sites (liver and spleen). In time myelofibrosis occurs.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In polycythemia vera (PV), treatment with chlorambucil and radioactive phosphorus (p32) increases the risk of leukemic transformation from 1% to 13-14%." | 7.69 | Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. ( Fisher, SG; Godwin, J; Nand, S; Stock, W, 1996) |
| "In studies to determine the optimal treatment for polycythemia vera, 431 previously untreated patients whose disease met established diagnostic criteria were entered into a prospective, randomized controlled trial between 1967 and 1974." | 6.65 | Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy. ( Berk, PD; Donovan, PB; Ellis, JT; Goldberg, JD; Landaw, SA; Laszlo, J; Najean, Y; Pisciotta, AV; Silverstein, MN; Wasserman, LR; Weinfeld, A, 1981) |
| " Randomized studies have shown that the risk of thrombosis was significantly reduced in ET with the use of hydroxyurea (HU) and in PV with the use of chlorambucil or 32P." | 4.80 | Treatment of polycythaemia vera and essential thrombocythaemia. ( Silverstein, MN; Tefferi, A, 1998) |
| "In polycythemia vera (PV), treatment with chlorambucil and radioactive phosphorus (p32) increases the risk of leukemic transformation from 1% to 13-14%." | 3.69 | Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. ( Fisher, SG; Godwin, J; Nand, S; Stock, W, 1996) |
| "A 73-year-old female developed pulmonary disease during treatment with chlorambucil for polycythemia vera." | 3.66 | Pulmonary disease with chlorambucil therapy. ( Cole, SR; Klatsky, AU; Myers, TJ, 1978) |
| "In studies to determine the optimal treatment for polycythemia vera, 431 previously untreated patients whose disease met established diagnostic criteria were entered into a prospective, randomized controlled trial between 1967 and 1974." | 2.65 | Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy. ( Berk, PD; Donovan, PB; Ellis, JT; Goldberg, JD; Landaw, SA; Laszlo, J; Najean, Y; Pisciotta, AV; Silverstein, MN; Wasserman, LR; Weinfeld, A, 1981) |
| "Its use in the treatment of essential thrombocythemia began later in 1950." | 2.41 | Treatment of the myeloproliferative disorders with 32P. ( Berlin, NI, 2000) |
| "The excess risk of cancer after chlorambucil appears to persist for 5 years after stopping this treatment." | 1.29 | The very-long-term course of polycythaemia: a complement to the previously published data of the Polycythaemia Vera Study Group. ( Dresch, C; Najean, Y; Rain, JD, 1994) |
| "Simultaneous presentation of chronic lymphocytic leukemia and polycythemia vera is reported in a previously untreated patient." | 1.28 | Coexistent chronic lymphocytic leukemia and polycythemia vera requiring no treatment. ( Botelho de Sousa, A; Gouveia, J, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 39 (79.59) | 18.7374 |
| 1990's | 7 (14.29) | 18.2507 |
| 2000's | 3 (6.12) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| WOODLIFF, HJ | 1 |
| Charbord, P | 1 |
| Neel, H | 1 |
| Caillou, B | 1 |
| Eydoux, P | 1 |
| Gardet, P | 1 |
| Parmentier, C | 1 |
| Freedman, ML | 1 |
| Berk, PD | 3 |
| Goldberg, JD | 3 |
| Silverstein, MN | 4 |
| Weinfeld, A | 2 |
| Donovan, PB | 3 |
| Ellis, JT | 3 |
| Landaw, SA | 3 |
| Laszlo, J | 3 |
| Najean, Y | 8 |
| Pisciotta, AV | 2 |
| Wasserman, LR | 7 |
| Brodsky, I | 1 |
| Morrison, JC | 1 |
| Dresch, C | 6 |
| Balcerzak, SP | 1 |
| Berlin, NI | 3 |
| McIntyre, OR | 1 |
| Tartaglia, AP | 1 |
| Tatarsky, I | 1 |
| Rain, JD | 4 |
| Nand, S | 1 |
| Stock, W | 1 |
| Godwin, J | 1 |
| Fisher, SG | 1 |
| Sánchez Fayos, J | 1 |
| Román Barbero, A | 1 |
| Nevado Reviriego, I | 1 |
| Tefferi, A | 1 |
| Pearson, TC | 1 |
| Messinezy, M | 1 |
| Lengfelder, E | 1 |
| Hehlmann, R | 1 |
| Hoffman, R | 1 |
| Queisser, W | 1 |
| Kalb, M | 1 |
| Cole, SR | 1 |
| Myers, TJ | 1 |
| Klatsky, AU | 1 |
| Westin, J | 1 |
| Maurice, P | 1 |
| Loeb, V | 1 |
| Newton, LK | 1 |
| Haq, AU | 1 |
| Botelho de Sousa, A | 1 |
| Gouveia, J | 1 |
| Conley, CL | 1 |
| Burger, T | 2 |
| Schmelczer, M | 2 |
| Molnár, L | 2 |
| Pajor, L | 2 |
| Koszorus, S | 2 |
| Meregalli, M | 1 |
| Fruchtman, SM | 1 |
| Peterson, P | 1 |
| Geller, SA | 1 |
| Rappaport, H | 1 |
| Hennemann, HH | 2 |
| Stecher, G | 2 |
| Libre, EP | 1 |
| Lewis, SM | 1 |
| Szur, L | 1 |
| Waldenström, JG | 1 |
| Delobel, J | 1 |
| Pecking, A | 1 |
| Kutti, J | 1 |
| Gilbert, HS | 2 |
| Krauss, S | 1 |
| Pasternack, B | 1 |
| Herbert, V | 1 |
| Binder, RA | 1 |
| Baxter, MF | 1 |
| Reinfrank, RF | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Benefit/Risk Profile of Pegylated Proline-Interferon Alpha-2b (AOP2014) Added to the Best Available Strategy Based on Phlebotomies in Low-risk Patients With Polycythemia Vera (PV). The Low-PV Randomized Trial[NCT03003325] | Phase 2 | 127 participants (Actual) | Interventional | 2017-02-02 | Completed | ||
| Multicenter Phase 2 Study of Efficacy and Safety of Pegylated Interferon-alfa 2a in Polycythemia Vera Patients[NCT00241241] | Phase 2 | 40 participants | Interventional | 2004-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
10 reviews available for chlorambucil and Polycythemia Vera
| Article | Year |
|---|---|
Busulphan treatment of polycythaemia vera.
Topics: Busulfan; Chlorambucil; Clinical Trials as Topic; Humans; Leukemia; Polycythemia Vera | 1982 |
The very long-term evolution of polycythemia vera: an analysis of 318 patients initially treated by phlebotomy or 32P between 1969 and 1981.
Topics: Aged; Antineoplastic Agents, Alkylating; Chlorambucil; Follow-Up Studies; Humans; Middle Aged; Phleb | 1997 |
[Efficacious treatment of a fatal blood disease: polycythemia vera].
Topics: Acute Disease; Alkylating Agents; Busulfan; Chlorambucil; Humans; Hydroxyurea; Leukemia, Myeloid; Le | 1997 |
Treatment of polycythaemia vera and essential thrombocythaemia.
Topics: Adult; Aged; Aspirin; Chlorambucil; Disease Progression; Female; Hemorrhage; Humans; Hydroxyurea; In | 1998 |
Treatment of the myeloproliferative disorders with 32P.
Topics: Adult; Aged; Alkylating Agents; Chlorambucil; Clinical Trials as Topic; Combined Modality Therapy; D | 2000 |
Idiopathic erythrocytosis, diagnosis and clinical management.
Topics: Aged; Arterial Occlusive Diseases; Bone Marrow; Chlorambucil; Diagnosis, Differential; Endocrine Sys | 2001 |
Natural history and management of polycythemia vera.
Topics: Acute Disease; Adult; Antineoplastic Agents; Bloodletting; Cell Transformation, Neoplastic; Chloramb | 1979 |
Treatment of polycythaemia vera.
Topics: Bloodletting; Busulfan; Chlorambucil; Cyclophosphamide; Humans; Injections, Intravenous; Internation | 1975 |
Neurologic complications of polycythemia and their impact on therapy.
Topics: Bloodletting; Chlorambucil; Clinical Protocols; Combined Modality Therapy; Humans; Nervous System Di | 1990 |
Current management of polycythemia vera and related diseases.
Topics: Allopurinol; Bloodletting; Chlorambucil; Erythropoiesis; Gout; Humans; Melphalan; Phosphorus Radiois | 1974 |
6 trials available for chlorambucil and Polycythemia Vera
| Article | Year |
|---|---|
Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy.
Topics: Acute Disease; Chlorambucil; Clinical Trials as Topic; Dose-Response Relationship, Drug; Humans; Leu | 1981 |
Busulphan treatment of polycythaemia vera.
Topics: Busulfan; Chlorambucil; Clinical Trials as Topic; Humans; Leukemia; Polycythemia Vera | 1982 |
Maintenance therapy of 32P-induced remission in polycythemia vera. A clinical trial of chlorambucil and hydroxy-urea in 109 cases.
Topics: Chlorambucil; Drug Tolerance; Humans; Hydroxyurea; Long-Term Care; Phosphorus Radioisotopes; Polycyt | 1978 |
The choice of treatment in polycythaemia vera.
Topics: Bloodletting; Chlorambucil; Clinical Trials as Topic; Humans; Hydroxyurea; Phosphorus Radioisotopes; | 1986 |
Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols.
Topics: Acute Disease; Age Factors; Bloodletting; Chlorambucil; Combined Modality Therapy; False Positive Re | 1986 |
Studies of the bone marrow in polycythemia vera and the evolution of myelofibrosis and second hematologic malignancies.
Topics: Acute Disease; Aged; Bloodletting; Bone Marrow; Bone Marrow Cells; Chlorambucil; Combined Modality T | 1986 |
34 other studies available for chlorambucil and Polycythemia Vera
| Article | Year |
|---|---|
IN-VITRO SENSITIVITY TESTS OF LEUKAEMIC CELLS TO CHEMOTHERAPEUTIC AGENTS.
Topics: Aminopterin; Animals; Antineoplastic Agents; Busulfan; Chlorambucil; Cyclophosphamide; Geriatrics; H | 1964 |
Redistribution of granulopoiesis from extramedullary territories to bone marrow in a case of spent polycythemia treated with alkylating agents.
Topics: Biopsy; Blood Cell Count; Bone Marrow; Busulfan; Chlorambucil; Female; Granulocytes; Humans; Karyoty | 1984 |
Common hematologic problems: diagnosis and treatment.
Topics: Aged; Anemia; Anemia, Macrocytic; Blood Cell Count; Blood Transfusion; Chlorambucil; Erythrocyte Ind | 1983 |
Polycythemia vera and alkylating agents.
Topics: Alkylating Agents; Chlorambucil; Humans; Leukemia; Polycythemia Vera | 1982 |
Myelosuppression in polycythemia vera: chemotherapy or radiotherapy?
Topics: Bone Marrow; Busulfan; Chlorambucil; Cyclophosphamide; Humans; Melphalan; Phosphorus Radioisotopes; | 1982 |
Influence of therapy on causes of death in polycythemia vera.
Topics: Chlorambucil; Hematocrit; Humans; Leukemia; Platelet Count; Polycythemia Vera; Risk; Thrombosis; Vei | 1981 |
The very-long-term course of polycythaemia: a complement to the previously published data of the Polycythaemia Vera Study Group.
Topics: Aged; Bloodletting; Chlorambucil; Follow-Up Studies; Humans; Middle Aged; Neoplasms; Phosphorus Radi | 1994 |
Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
Topics: Acute Disease; Anemia, Refractory, with Excess of Blasts; Busulfan; Cell Transformation, Neoplastic; | 1996 |
[Treatment of polycythemia vera].
Topics: Antineoplastic Agents, Alkylating; Blood Component Removal; Chlorambucil; Erythrocyte Transfusion; H | 2001 |
[Secondary carcinoma: a complication of cytostatic therapy?].
Topics: Antineoplastic Agents; Breast Neoplasms; Carcinogens; Chlorambucil; Female; Humans; Immunosuppressio | 1979 |
Myeloproliferative diseases.
Topics: Adult; Aged; Chlorambucil; Female; Humans; Male; Melphalan; Middle Aged; Myeloproliferative Disorder | 1977 |
Pulmonary disease with chlorambucil therapy.
Topics: Aged; Chlorambucil; Female; Humans; Polycythemia Vera; Pulmonary Alveoli; Pulmonary Fibrosis | 1978 |
Chromosome abnormalities after chlorambucil therapy of polycythaemia vera.
Topics: Aged; Bone Marrow; Bone Marrow Cells; Chlorambucil; Chromosome Aberrations; Chromosome Deletion; Fem | 1976 |
[The treatment of myeloproliferative syndromes].
Topics: Aged; Bloodletting; Busulfan; Chlorambucil; Female; Humans; Leukemia, Myeloid; Male; Myeloproliferat | 1975 |
The treatment of polycythemia vera.
Topics: Blood Transfusion; Bloodletting; Bone Marrow; Bone Marrow Cells; Chlorambucil; Chronic Disease; Eryt | 1976 |
Transformation of polycythemia vera to Ph-positive chronic myelogenous leukemia.
Topics: Bloodletting; Cell Transformation, Neoplastic; Chlorambucil; Humans; Leukemia, Myeloid, Acute; Leuko | 1990 |
Coexistent chronic lymphocytic leukemia and polycythemia vera requiring no treatment.
Topics: Aged; Aged, 80 and over; Bloodletting; Chlorambucil; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; | 1989 |
Polycythemia vera, diagnosis and treatment.
Topics: Aged; Blood Pressure; Bloodletting; Cerebrovascular Disorders; Chlorambucil; Diagnosis, Differential | 1987 |
Course and transformation of polycythaemia vera in relation to therapy.
Topics: Adult; Aged; Aged, 80 and over; Chlorambucil; Female; Humans; Leukemia; Leukemia, Radiation-Induced; | 1988 |
[Clinical course and transformation of polycythemia vera and its relation to applied therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Busulfan; Chlorambucil; Combined Modali | 1987 |
[A case of chronic lymphatic leukemia associated with polycythemia vera].
Topics: Aged; Chlorambucil; Humans; Leukemia, Lymphoid; Male; Polycythemia Vera; Prednisone | 1987 |
Acute leukemia in polycythemia vera.
Topics: Acute Disease; Antigens, Neoplasm; Bloodletting; Chlorambucil; Chromosome Aberrations; Chromosome Di | 1986 |
A cooperative study of polycythemia vera.
Topics: Aspirin; Chlorambucil; Dipyridamole; Humans; Leukemia; Polycythemia Vera; Prognosis | 1985 |
[The therapy of polycythemia vera].
Topics: Alkylating Agents; Anticoagulants; Bloodletting; Busulfan; Chlorambucil; Histamine H1 Antagonists; H | 1967 |
Polycythemia: a disease of all ages.
Topics: Adult; Aged; Alkaline Phosphatase; Blood Platelets; Blood Volume; Bone Marrow; Chlorambucil; Erythro | 1974 |
Blood and neoplastic diseases. Myeloproliferative disorders.
Topics: Adrenal Cortex Hormones; Androgens; Blood Transfusion; Bloodletting; Busulfan; Chlorambucil; Cycloph | 1974 |
From bad to worse? Treatment and leukemogenesis.
Topics: Antibiotics, Antineoplastic; Busulfan; Chlorambucil; Chromosome Aberrations; Chromosome Disorders; H | 1973 |
[Choice of treatment in polycythemia vera. 1. Efficacy of chemotherapy].
Topics: Chlorambucil; Humans; Hydroxyurea; Melphalan; Phosphorus Isotopes; Polycythemia Vera; Remission, Spo | 1973 |
Platelet production rate in polycythemia vera after myelosuppressive therapy.
Topics: Aged; Blood Cell Count; Blood Platelets; Busulfan; Cell Division; Cell Survival; Chlorambucil; Chrom | 1972 |
Pipobroman (Vercyte) - a new antineoplastic drug.
Topics: Anemia, Hemolytic; Antineoplastic Agents; Bone Marrow; Busulfan; Chlorambucil; Gastrointestinal Hemo | 1967 |
[Therapy of polycythemia vera].
Topics: Antimetabolites; Antineoplastic Agents; Bloodletting; Busulfan; Chlorambucil; Cyclophosphamide; Huma | 1969 |
Serum vitamin B12 content and unsaturated vitamin B12-binding capacity in myeloproliferative disease. Value in differential diagnosis and as indicators of disease activity.
Topics: Adult; Aged; Blood Proteins; Bloodletting; Chlorambucil; Chromatography; Cyclophosphamide; Diagnosis | 1969 |
Muramidase in polycythemia vera.
Topics: Alkaline Phosphatase; Busulfan; Chlorambucil; Cyclophosphamide; Humans; Leukocyte Count; Muramidase; | 1970 |
Electrophoretic patterns of human leukocyte alkaline phosphatase in polycythemia vera.
Topics: Alkaline Phosphatase; Busulfan; Chlorambucil; Electrophoresis; Gels; Humans; Leukocytes; Phosphorus | 1971 |